Home  |  Contact

UniProtKB/Swiss-Prot P04075: Variant p.Asp129Gly

Fructose-bisphosphate aldolase A
Gene: ALDOA
Chromosomal location: 16q22-q24
Variant information

Variant position:  129
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Aspartate (D) to Glycine (G) at position 129 (D129G, p.Asp129Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (D) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Glycogen storage disease 12 (GSD12) [MIM:611881]: A metabolic disorder associated with increased hepatic glycogen and hemolytic anemia. It may lead to myopathy with exercise intolerance and rhabdomyolysis. {ECO:0000269|PubMed:14615364, ECO:0000269|PubMed:14766013, ECO:0000269|PubMed:2229018, ECO:0000269|PubMed:2825199, ECO:0000269|PubMed:8598869}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In GSD12; thermolabile.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  129
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  364
The length of the canonical sequence.

Location on the sequence:   VDKGVVPLAGTNGETTTQGL  D GLSERCAQYKKDGADFAKWR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADFAKWR

Chimpanzee                    VDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADFAKWR

Mouse                         VDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADFAKWR

Rat                           VDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADFAKWR

Rabbit                        VDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADFAKWR

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 364 Fructose-bisphosphate aldolase A
Binding site 147 – 147 Substrate
Modified residue 111 – 111 N6-acetyllysine; alternate
Modified residue 111 – 111 N6-malonyllysine; alternate
Modified residue 132 – 132 Phosphoserine


Literature citations

Human aldolase A deficiency associated with a hemolytic anemia: thermolabile aldolase due to a single base mutation.
Kishi H.; Mukai T.; Hirono A.; Fujii H.; Miwa S.; Hori K.;
Proc. Natl. Acad. Sci. U.S.A. 84:8623-8627(1987)
Cited for: VARIANT GSD12 GLY-129; CHARACTERIZATION OF VARIANT GSD12 GLY-129;

Human aldolase A of a hemolytic anemia patient with Asp-128-->Gly substitution: characteristics of an enzyme generated in E. coli transfected with the expression plasmid pHAAD128G.
Takasaki Y.; Takahashi I.; Mukai T.; Hori K.;
J. Biochem. 108:153-157(1990)
Cited for: CHARACTERIZATION OF VARIANT GSD12 GLY-129;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.